HIGHLIGHTS
- who: Po-Huang Chen et al. from the Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan have published the paper: Benefit of Uracil-Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer, in the Journal: Medicina 2023, 10 of 31/Dec/2015
- what: Our results show that the DFS improved significantly in patients with stage IIA colon cancer receiving UFT as a postoperative adjuvant chemotherapy compared with the DFS in the observation group.
- how: The authors conducted a population-based cohort study in patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.